MedTrace Logo

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2024-05-03

No results posted yet for this study

Summary

This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.

Conditions

Interventions

DRUG

Sonelokimab (M1095)

randomized treatment; parallel-group

DRUG

Adalimumab

randomized treatment; parallel-group

OTHER

Placebo

randomized treatment; parallel-group

Sponsors & Collaborators

  • MoonLake Immunotherapeutics AG

    lead INDUSTRY

Principal Investigators

  • Prof. Kristian Reich, M.D., Ph.D. (equ.) · MoonLake Immunotherapeutics AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2023-05-09
Completion
2023-08-30
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Germany
  • Ireland
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322473 on ClinicalTrials.gov